S
Synthego
Provider of synthetic RNA solutions for CRISPR genome engineering
About Synthego
Synthego is a biotechnology company that operates in the field of genetic engineering. It specializes in providing synthetic RNA (ribonucleic acid) and gene editing tools. RNA is a molecule that plays a crucial role in coding, decoding, regulation, and expression of genes. In simpler terms, Synthego's products help scientists to modify genes, which can lead to breakthroughs in treating diseases or improving crop yields.
Read full description
The company serves a diverse range of clients, including research institutions, pharmaceutical companies, and biotech startups. These clients use Synthego's products for various purposes, such as drug discovery, disease modeling, and genetic research.
Synthego operates in the rapidly growing market of genetic engineering and synthetic biology. The demand for its products is driven by the increasing investment in genetic research and the growing application of gene editing in various fields.
The company's business model revolves around the production and sale of synthetic RNA and gene editing tools. It generates revenue by selling these products directly to its clients. Additionally, Synthego also offers a platform for genetic engineering, which provides users with access to advanced gene editing capabilities.
In conclusion, Synthego is a key player in the genetic engineering market, providing essential tools and services for gene editing and research. Its innovative products and platform have positioned it well to capitalize on the growing demand for genetic engineering solutions.
At a glance
- Status
- Acquired
- Founded
- 2012
- Headquarters
- Menlo Park, United States
- Employees
- 170
- Open positions
- 3
- Dealroom signal
- 69.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Industrial Automation, Innovation Management, Biotechnology, DNA, Genetics and genomics, Synthetic Biology, Crispr, Genome Engineering, Rumoured $1B, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUTOther financing | Jul 2025 | $0 | — | Perceptive Advisors | ↗ |
| SERIES EOther financing | Feb 2022 | $200M | $800M | RA Capital Management · Declaration Partners · Moore Strategic Ventures · Chimera | ↗ |
Growth signals
Latest recorded traffic for Synthego is 120K monthly website visits, up 34.8% over the last three months. Synthego's team grew 3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Menlo Ventures
WI Harper Group
Founders Fund
8VC
Arab Angel Fund
SciFi VC
OS Fund
Alexandria Venture Investments
ZhenFund
Jerry Yang
Intel Capital
Series B and later10 investors entered at this stage
RA Capital Management
Wellington Management
Perceptive Advisors
Declaration Partners
Moore Strategic Ventures
Chimera
SoftBank
Logos Capital
Gigafund
Laurion Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synthego on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synthego’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.